U.S. Health Care REITs Stock News

NYSE:EL
NYSE:ELPersonal Products

Estée Lauder (EL) Returns To Quarterly Profit As EPS Recovery Tests Bearish Narratives

Estée Lauder Companies (EL) has put fresh numbers on the table for its latest quarter, with Q2 2026 revenue of US$4.2b and basic EPS of US$0.45, set against a trailing twelve month picture that still shows a basic EPS loss of US$0.49 on revenue of US$14.7b. Over recent quarters, the company has seen revenue move between US$3.4b and US$4.0b in fiscal 2025, before reaching US$3.5b in Q1 2026 and US$4.2b in Q2 2026. Basic EPS has ranged from losses of around US$1.64 per share to a recent profit...
NYSE:AOS
NYSE:AOSBuilding

A. O. Smith Cuts 2026 Outlook As China Weakness And U.S. Issues Bite

A. O. Smith (NYSE:AOS) reported Q1 2026 results that missed expectations, citing weak demand in China and production issues at its Ashland City facility. The company lowered its full-year 2026 guidance for both sales and earnings, reflecting softer performance and operational challenges. Management outlined a targeted restructuring of the North America water treatment business and plans for price increases to address higher input costs. A. O. Smith, a manufacturer of water heaters and water...
NYSE:DBRG
NYSE:DBRGCapital Markets

A Look At DigitalBridge Group (DBRG) Valuation After Strong 1-Year Returns And Mixed Multiple Signals

DigitalBridge Group (DBRG) continues to draw attention as investors weigh its role in digital infrastructure against recent share performance. The stock last closed at US$15.55 and has a market value of about US$2.9b. See our latest analysis for DigitalBridge Group. While the recent 1-day and 7-day share price returns are slightly negative, DigitalBridge Group’s 1-year total shareholder return of 69.55% contrasts with a 5-year total shareholder return decline of 43.82%. This suggests momentum...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Apellis Cell And Gene Update Puts Growth Story In Investor Focus

Apellis Pharmaceuticals (NasdaqGS:APLS) is scheduled to present at the 2026 Cell & Gene Meeting on the Mediterranean. The conference appearance will focus on the company’s cell and gene therapy programs. The event is expected to draw interest from biotech specialists and investors who track emerging therapeutic platforms. Apellis Pharmaceuticals (NasdaqGS:APLS) is known for work in complement biology, and its upcoming presence at the 2026 Cell & Gene Meeting on the Mediterranean puts a...
NYSE:SAH
NYSE:SAHSpecialty Retail

Is Sonic Automotive (SAH) Getting Ahead Of Itself After Strong Recent Share Price Gains

Wondering whether Sonic Automotive's current share price lines up with its underlying value, or if the recent attention has run ahead of the fundamentals? The stock last closed at US$76.43, with returns of 6.4% over 7 days, 17.1% over 30 days, 24.0% year to date, 24.5% over 1 year, 101.2% over 3 years and 64.1% over 5 years. These figures may catch the eye of investors reviewing performance over different time frames. Recent coverage of US auto retailers has focused on how dealers are...
NYSE:OGN
NYSE:OGNPharmaceuticals

Organon Buyout And POHERDY Approval Shape Returns And Valuation Outlook

Organon (NYSE:OGN) has agreed to be acquired by Sun Pharmaceutical Industries in an all cash deal valued at about $11.75b. The transaction is expected to close in early 2027, after which Organon is set to be delisted from the NYSE. Separately, Organon and Henlius have received European marketing approval for POHERDY, the first biosimilar to PERJETA. For investors watching NYSE:OGN, these developments arrive after a sharp recent move in the share price. The stock closed at $13.29, with...
NYSE:PEN
NYSE:PENMedical Equipment

Is Penumbra (PEN) Pricing In Too Much Growth After Recent Trial Developments

Wondering if Penumbra at around US$325.33 is offering you real value or just a rich price tag? This article walks through what the latest numbers actually say about the stock. The share price shows a 1.4% decline over the last 7 days and a 1.1% decline over the last 30 days, while returns stand at 5.1% year to date and 9.9% over the past year. Recent coverage around Penumbra has focused on its position in the medical equipment space and how investors are weighing growth potential against...
NYSE:APAM
NYSE:APAMCapital Markets

Artisan Partners Weighs Acquisitions And New Credit Strategies With Excess Capital

Artisan Partners Asset Management (NYSE:APAM) is signaling a push into acquisitions and new investment strategies in differentiated credit, private equity and real assets. Management has highlighted an active M&A pipeline, interest in both individual hires and larger deals, and continued R&D efforts to expand the firm’s platform. The company plans to pursue these opportunities while keeping significant excess capital available for potential transactions and organic growth...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

Is Zions Bancorporation (ZION) Still Attractively Priced After Strong Three Year Share Gains

If you are wondering whether Zions Bancorporation National Association is priced attractively right now, it helps to start with what the recent share performance and valuation checks are signaling. The stock last closed at US$63.26, with returns of 3.1% over 7 days, 8.6% over 30 days, 6.8% year to date, 40.3% over 1 year and 199.5% over 3 years, while the 5 year return stands at 26.7%. Recent headlines around US banks, including Zions Bancorporation National Association, have focused on...
NYSE:HIW
NYSE:HIWOffice REITs

Is It Time To Reassess Highwoods Properties (HIW) After Its Recent Share Price Rebound?

Investors may be wondering whether Highwoods Properties at around US$24.71 is starting to look like value, or if the price still does not quite stack up. The stock has recently shown mixed returns, with a 3.4% gain over 7 days and 15.4% over 30 days, set against a 4.5% decline year to date and an 8.9% decline over the past year. Recent coverage has focused on how office focused real estate investment trusts fit into investors' portfolios as hybrid work patterns and demand for office space...
NYSE:CR
NYSE:CRMachinery

Crane Q1 Acquisition Gains Support Higher 2026 Guidance And Growth Plans

Crane Company (NYSE:CR) reported a strong Q1 2026, with net sales supported by the integration of several recent acquisitions. Management raised full year 2026 guidance and outlined plans for further M&A, citing a solid acquisition pipeline and balance sheet. The company is targeting significant total sales growth for 2026, with recent deals already contributing earlier than initially expected. Crane Company, traded as NYSE:CR, operates as a diversified industrial business, supplying...
NasdaqGS:VTRS
NasdaqGS:VTRSPharmaceuticals

Viatris Contraceptive Patch Data Puts Women’s Health Growth Story In Focus

Viatris (NasdaqGS:VTRS) is presenting pivotal Phase 3 results for its investigational low dose estrogen contraceptive weekly patch at a major scientific meeting. The U.S. FDA has accepted the New Drug Application for the patch and set a target action date in July 2026. The product is positioned within Viatris' women's health franchise and represents a potential new entrant in the contraceptive market. For investors tracking NasdaqGS:VTRS, this contraceptive patch sits within a broader...
NasdaqGS:SRAD
NasdaqGS:SRADHospitality

Is Sportradar Group (SRAD) Pricing Look Compelling After Recent Share Price Slide

Wondering whether Sportradar Group's current share price reflects its true worth, or if the market is mispricing the story. The stock last closed at US$13.26, with returns of 0.2% over 7 days, a 20.3% decline over 30 days, and year to date and 1 year returns of 43.1% and 44.1% declines, while the 3 year return sits at 1.8%. Recent coverage has focused on Sportradar Group as a listed sports data and technology provider, with attention on how it is positioned in the wider sports betting and...
NYSE:FR
NYSE:FRIndustrial REITs

First Industrial Adds Director After Activist Push What It Means For FR

First Industrial Realty Trust expanded its board and appointed Frank E. Schmitz as an independent director. The move follows a recent activist investor campaign focused on board composition and governance. The appointment comes in a contested board setting, signaling a response to shareholder pressure. For investors watching NYSE:FR, this board change occurs at a time when the stock is trading at $62.14 and has returned 31.2% over the past year and 44.6% over the past five years. Those...
NasdaqGS:GEN
NasdaqGS:GENSoftware

Gen Digital Targets AI Trust Layer With xAI Tie Up And VPN For Agents

Gen Digital (NasdaqGS:GEN) has partnered with xAI to bring Grok large language models into its consumer platforms via the Gen AI Foundry. The company is launching VPN for Agents, presented as an industry first security tool tailored to autonomous AI agents. Gen Digital is also expanding Norton AI Agent Protection to address new cyber risks created by AI driven agents. Gen Digital, trading at $19.37, is adding these AI focused efforts on top of a share performance record that includes a...
NasdaqGS:UCTT
NasdaqGS:UCTTSemiconductor

Ultra Clean Updates Board Leadership As AI Cycle Shapes Capital Choices

Ultra Clean Holdings (NasdaqGS:UCTT) announced that Clarence Granger will step down as Chairman of the Board effective May 22, 2026. Tom Edman has been appointed to assume the Chairman role as the company adjusts its leadership at the board and executive levels. This change follows a period of executive transitions while the sector is influenced by increased AI related investment. Ultra Clean Holdings, trading at $74.61, has seen sharp share price moves recently, including a 10.1% decline...
NYSE:PLGO
NYSE:PLGOInsurance

Fidelis Buyback And Bye Law Changes Reframe Capital Return Outlook

Fidelis Insurance Holdings (NYSE:FIHL) has entered into a major share repurchase agreement that ends founding shareholder CVC Falcon Holdings Limited's ownership stake. The company has also approved amendments to its Bye Laws at its latest annual meeting, signaling changes to its governance framework. These decisions mark a meaningful shift in ownership and corporate rules that is relevant for existing and prospective shareholders. Fidelis Insurance Holdings, a specialty insurance and...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed

The Gross Law Firm recently announced a class action lawsuit on behalf of Oddity Tech shareholders, alleging the company made materially false and misleading statements about digital advertising costs after an algorithm change by its largest advertising partner increased customer acquisition costs and hurt its business outlook. This legal challenge raises fresh questions about how dependent Oddity’s business model is on a single digital ad ecosystem and the transparency of its cost...
NYSE:PRI
NYSE:PRIInsurance

Primerica Household Budget Index Signals Stable Clients And Supports PRI Valuation

Primerica released its latest Household Budget Index, showing middle-income family finances are stabilizing despite ongoing cost pressures. The HBI has remained above 100 for nine consecutive months, indicating that middle-income households are maintaining improved purchasing power. The data offers a fresh read on consumer resilience, which is closely watched by investors tracking trends in spending and financial health. For investors following Primerica (NYSE:PRI), the new Household Budget...
NasdaqGS:COKE
NasdaqGS:COKEBeverage

Vanguard’s Passive Stake Meets Coca-Cola Consolidated Valuation And Momentum Story

Vanguard Capital Management and Vanguard Portfolio Management have each disclosed beneficial ownership above 5% in Coca-Cola Consolidated. The filings show that a substantial portion of NasdaqGS:COKE shares is now held passively, with no stated intent to influence management or operations. This change adds a large, long term oriented institution to the shareholder register, which may interest both existing and prospective investors. Coca-Cola Consolidated, listed on NasdaqGS:COKE, last...